Risk | Very High |
---|---|
Min SIP Amount | ₹500 |
Expense Ratio | 1.79% |
NAV | ₹162.52 (20 Apr 2021) |
---|---|
Fund Started | 01 Jan 2013 |
Fund Size | ₹618 Cr |
Name | Sector | Instrument | % Assets |
---|---|---|---|
Aurobindo Pharma Ltd. | Healthcare | Equity | 9.6% |
Cipla Ltd. | Healthcare | Equity | 9.5% |
Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 9.5% |
Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 8.4% |
Divi's Laboratories Ltd. | Healthcare | Equity | 6.2% |
Eris Lifesciences Ltd | Healthcare | Equity | 5.7% |
Cadila Healthcare Ltd. | Healthcare | Equity | 5.4% |
Fortis Healthcare Ltd. | Healthcare | Equity | 4.4% |
Ajanta Pharma Ltd. | Healthcare | Equity | 4.1% |
JB Chemicals & Pharmaceuticals Ltd. | Healthcare | Equity | 3.6% |
UTI Healthcare Fund Direct Growth is a Equity Mutual Fund Scheme launched by UTI Mutual Fund. This scheme was made available to investors on 01 Jan 2013. V Srivatsa, Ritesh Rathod is the Current Fund Manager of UTI Healthcare Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹618 Cr and the Latest NAV as of 20 Apr 2021 is ₹162.52.
The UTI Healthcare Fund Direct Growth is rated Very High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 30 days.
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.